|
Synonyms: FPA-144 | FPA144
Compound class:
Antibody
Comment: Bemarituzumab (FPA144) is first-in-class anti-fibroblast growth factor receptor 2b (FGFR2b) chemotherapy antibody from Five Prime Therapeutics [3]. Amgen acquired Five Prime in 2021. Bemarituzumab is a humanized immunoglobulin G1 (IgG1) isotype antibody. It binds to FGFR2b and promotes ADCC via enhanced binding to FcγRIIIa. Around 30% of HER2-negative gastric cancers are FGFR2b positive and bemarituzumab is designed to target this cancer subtype that uses the FGF/FGFR pathway to promote transformation, proliferation and angiogenesis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Bemarituzumab (FPA144) has progressed to clinical evaluation as an immuno-oncology therapeutic for advanced gastrointestinal cancers [4]. In November 2020 Five Prime Therapeutics announced that bemarituzumab showed statistically significant efficacy against all three pre-determined endpoints in a subgroup of patients with FGFR2b +ve gastric tumours. Since FGFR2b is expressed across a range of cancers that arise from epithelial cells (e.g. squamous NSCLC, breast, ovarian and pancreatic cancers and others) bemarituzumab offers potential for cancers beyond the stomach. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02318329 | Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | Phase 1 Interventional | Five Prime Therapeutics, Inc. | Bemarituzumab demonstrated clinical activity as a monotherapy in patients with FGFRb +ve late-line gastric cancer. | 1-2 |
| NCT03694522 | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) | Phase 2 Interventional | Five Prime Therapeutics, Inc. | This study is known as the FIGHT trial. | 3 |
| NCT03343301 | A Study of FPA144 Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | Phase 1 Interventional | Five Prime Therapeutics, Inc. | This is known as the FIGHT trial. | 1 |
